Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [26]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1107864 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Interleukin 6 (IL6) antibody
- Antibody type
- Monoclonal
- Description
- Ion Exchange Chromatography
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- B-E8
- Vial size
- 0.5 mg
- Storage
- Store the antibody undiluted at 2-8°C.
Submitted references Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.
Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation.
Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages.
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints.
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Coming of age: anti-cytokine therapies.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
STAT3 is constitutively activated in Hodgkin cell lines.
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.
Human anti-animal antibody interferences in immunological assays.
Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.
Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis.
Preincubation of human resting T cell clones with interleukin 10 strongly enhances their ability to produce cytokines after stimulation.
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases.
Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.
In vivo role of IL-6 on the viral load and on immunological abnormalities of HIV-infected patients.
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Adam N, Rabe B, Suthaus J, Grötzinger J, Rose-John S, Scheller J
Journal of virology 2009 May;83(10):5117-26
Journal of virology 2009 May;83(10):5117-26
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B
Blood 2009 May 7;113(19):4614-26
Blood 2009 May 7;113(19):4614-26
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P
Blood 2006 May 1;107(9):3474-80
Blood 2006 May 1;107(9):3474-80
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL, Intergroupe Francophone du Myélome group.
Blood 2006 Jan 1;107(1):397-403
Blood 2006 Jan 1;107(1):397-403
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.
Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B
Critical care medicine 2004 May;32(5):1136-40
Critical care medicine 2004 May;32(5):1136-40
Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation.
Ancey C, Menet E, Corbi P, Fredj S, Garcia M, Rücker-Martin C, Bescond J, Morel F, Wijdenes J, Lecron JC, Potreau D
Cardiovascular research 2003 Jul 1;59(1):78-85
Cardiovascular research 2003 Jul 1;59(1):78-85
Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages.
Delneste Y, Charbonnier P, Herbault N, Magistrelli G, Caron G, Bonnefoy JY, Jeannin P
Blood 2003 Jan 1;101(1):143-50
Blood 2003 Jan 1;101(1):143-50
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints.
Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, Kraan M, Coleman M, Ahern MJ
Annals of the rheumatic diseases 2003 Apr;62(4):303-7
Annals of the rheumatic diseases 2003 Apr;62(4):303-7
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M
Blood 2002 Jul 1;100(1):194-9
Blood 2002 Jul 1;100(1):194-9
Coming of age: anti-cytokine therapies.
Song XY, Torphy TJ, Griswold DE, Shealy D
Molecular interventions 2002 Feb;2(1):36-46
Molecular interventions 2002 Feb;2(1):36-46
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.
Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A
Blood 2001 Mar 15;97(6):1590-7
Blood 2001 Mar 15;97(6):1590-7
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Feb 1;19(3):772-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Feb 1;19(3):772-8
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Feb 1;19(3):772-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Feb 1;19(3):772-8
STAT3 is constitutively activated in Hodgkin cell lines.
Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H
Blood 2001 Aug 1;98(3):762-70
Blood 2001 Aug 1;98(3):762-70
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY
Cancer research 2001 Apr 1;61(7):3096-104
Cancer research 2001 Apr 1;61(7):3096-104
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.
Gu ZJ, De Vos J, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J, Klein B
Leukemia 2000 Jan;14(1):188-97
Leukemia 2000 Jan;14(1):188-97
Human anti-animal antibody interferences in immunological assays.
Kricka LJ
Clinical chemistry 1999 Jul;45(7):942-56
Clinical chemistry 1999 Jul;45(7):942-56
Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.
Foussat A, Wijdenes J, Bouchet L, Gaidano G, Neipel F, Balabanian K, Galanaud P, Couderc J, Emilie D
European cytokine network 1999 Dec;10(4):501-8
European cytokine network 1999 Dec;10(4):501-8
Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis.
Stenger S, Niazi KR, Modlin RL
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 1;161(7):3582-8
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 1;161(7):3582-8
Preincubation of human resting T cell clones with interleukin 10 strongly enhances their ability to produce cytokines after stimulation.
Lelievre E, Sarrouilhe D, Morel F, Preud'Homme JL, Wijdenes J, Lecron JC
Cytokine 1998 Nov;10(11):831-40
Cytokine 1998 Nov;10(11):831-40
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B
British journal of haematology 1998 Mar;100(4):637-46
British journal of haematology 1998 Mar;100(4):637-46
IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases.
Doré P, Lelièvre E, Morel F, Brizard A, Fourcin M, Clemént C, Ingrand P, Daneski L, Gascan H, Wijdenes J, Gombert J, Preud'homme JL, Lecron JC
Clinical and experimental immunology 1997 Jan;107(1):182-8
Clinical and experimental immunology 1997 Jan;107(1):182-8
Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.
Kalai M, Montero-Julian FA, Grötzinger J, Fontaine V, Vandenbussche P, Deschuyteneer R, Wollmer A, Brailly H, Content J
Blood 1997 Feb 15;89(4):1319-33
Blood 1997 Feb 15;89(4):1319-33
In vivo role of IL-6 on the viral load and on immunological abnormalities of HIV-infected patients.
Marfaing-Koka A, Aubin JT, Grangeot-Keros L, Portier A, Benattar C, Merrien D, Agut H, Aucouturier P, Autran B, Wijdenes J
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996 Jan 1;11(1):59-68
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996 Jan 1;11(1):59-68
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B
Blood 1995 Oct 15;86(8):3123-31
Blood 1995 Oct 15;86(8):3123-31
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B
Blood 1995 May 1;85(9):2521-7
Blood 1995 May 1;85(9):2521-7
No comments: Submit comment
No validations: Submit validation data